Ecosystem Nourishment for Gut Restoration After Fecal Transplantation (ENGRAFT)
14 de septiembre de 2026 actualizado por: Sean Spencer, Stanford University
The purpose of this study is to test whether young-donor fecal microbiome transplantation (FMT) and a fermented, plant-rich high-fiber, microbiome rejuvenating diet (MRD) reduce inflammatory and biological aging markers.
Participants (≥40 years) will be randomized (1:1:1:1) for 8 weeks with 4-week follow-up to: (A) diet alone, (B) FMT alone, (C) diet + FMT, or (D) Placebo FMT.
We will use rigorously screened young and healthy FMT donors and encapsulated delivery.
Outcomes include change from baseline to end of dietary intervention (week 8) in markers of aging and inflammation.
Secondary outcomes include defining microbiome engraftment/diversity/function, key metabolites, diet adherence, and quality-of-life.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Descripción detallada
For this study, the research participant will receive a once daily oral dose of healthy young FMT and diet modification to increase fiber and fermented food consumption. Throughout the study's duration, the participant will provide stool, blood and urine samples as well as a series of health questionnaires to track the impact of the intervention.
*PROTOCOL OVERVIEW* The study will begin with the selection of possible participants through the samples collected through the Stanford Microbiome Bank (IRB 85544), the participants identified will be contacted through the appropriate channels and asked to complete a short online questionnaire if interested in continuing with being a part of the protocol.After completing the questionnaire, those selected will be contacted via phone to schedule an in person appointment in the Clinical and Translational Research Unit (CTRU). During this appointment, the study team will obtain informed consent and one stool sample. Their initial stool sample will be sent outside Stanford for microbiome composition analysis which will determine if the participant is a good candidate for the protocol.
After enrollment in the protocol, the participants will be randomized in a 1:1:1:1 ratio to one of four study arms: Placebo, placebo + diet, FMT no diet, or FMT + diet. Those randomized to one of the FMT groups will be instructed to take a single oral dose of young FMT (4 capsules) for two weeks, and those randomized to a diet arm will have an initial appointment with the study's dietitian to establish a microbiome rejuvenating diet (MRD) starting with a one week ramp up period and continued for a total of 8 weeks. The main factors incorporated into the MRD will be ~3 servings/day fermented foods and ≥30-40 g/day or +20g fiber(plant-based whole food), 5g of resistant starch supplements and 5g of psyllium husk.
Throughout their enrollment in the protocol, the participants will provide stool samples weekly for analysis and complete general health and lifestyle questionnaires to assess protocol adherence and any changes in their health status. On weeks 0, 2, 4, 8 & 12 participants will be asked to give a blood, urine and stool sample for further analysis and to complete a Nutrition Data System for Research (NDSR) questionnaire; stool is additionally collected at Week 6.
All patient samples will be coded and stored in Stanford facilities for further processing.
Tipo de estudio
Intervencionista
Inscripción (Estimado)
80
Fase
- Fase 2
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Roujheen Sabetan, MPH
- Número de teléfono: 650-498-8188
- Correo electrónico: rsabetan@stanford.edu
Copia de seguridad de contactos de estudio
- Nombre: Sean P Spencer, MD PhD
- Número de teléfono: 650-736-6555
- Correo electrónico: seanspen@stanford.edu
Ubicaciones de estudio
-
-
California
-
Stanford, California, Estados Unidos, 94305
- Stanford University
-
Contacto:
- Roujheen Sabetan, MPH
- Número de teléfono: 650-498-8188
- Correo electrónico: rsabetan@stanford.edu
-
Contacto:
- Sean P Spencer, MD PhD
- Número de teléfono: 650-736-6555
- Correo electrónico: seanspen@stanford.edu
-
Investigador principal:
- Sean P Spencer, MD PhD
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
- Able and willing to provide written informed consent prior to completion of any study procedures.
- Age ≥40 years at the time of consent.
- In generally good health, as determined by medical history, medication review, and investigator assessment.
- Willing and able to comply with all study procedures, assessments, and study-related restrictions for the duration of participation.
- Willing to adhere to the study's lifestyle considerations for the duration of the study (maintain usual diet unless assigned to the diet arm; maintain usual physical activity; avoid non-essential systemic antibiotics; avoid probiotic/prebiotic/synbiotic supplements).
- Willing and able to attend all required in-person study visits at Stanford University and complete remote assessments, if applicable.
Exclusion Criteria:
- Moderate or severe irritable bowel syndrome (IBS).
- Current or prior diagnosis of inflammatory bowel disease (IBD), including ulcerative colitis, Crohn's disease, or indeterminate colitis.
- Active gastrointestinal disease, including infectious gastroenteritis, colitis, gastritis, recurrent Clostridioides difficile infection, untreated Helicobacter pylori infection, or clinically significant malabsorption disorders (e.g., celiac disease).
- Major gastrointestinal surgery within the past 5 years (excluding cholecystectomy and appendectomy), or history of major bowel resection at any time.
- Body mass index (BMI) ≥40 kg/m².
- Diabetes mellitus.
- Hyperthyroidism or uncontrolled hypothyroidism.
- Clinically significant renal disease.
- Clinically significant hepatic disease or significant liver enzyme abnormalities.
- Clinically significant cardiovascular disease.
- Autoimmune or systemic inflammatory disease.
- Current malignancy or history of malignancy within the past 5 years, excluding adequately treated non-melanoma skin cancer.
- Current use of immunosuppressive medications, including systemic corticosteroids, thiopurines, methotrexate, calcineurin inhibitors, biologic agents, or other immunosuppressive therapies.
- Receipt of fecal microbiota transplantation (FMT) within the previous 12 months.
- Use of systemic antibiotic therapy within 30 days prior to enrollment or anticipated antibiotic use during the study period.
- Use of probiotic supplements, prebiotic supplements, synbiotics, or live microbial therapeutics within 30 days prior to enrollment.
- Current use or use within the previous 6 months of medications prescribed primarily for weight loss.
- Current use of medications known to significantly affect body weight unless the medication and dose have remained stable for at least 6 months prior to enrollment.
- Neurodevelopmental, psychiatric, neurological, or neuromuscular disorders that, in the opinion of the investigator, may impair the participant's ability to provide informed consent, comply with study procedures, or complete study assessments.
- Current diagnosis of schizophrenia, bipolar disorder, or other severe psychiatric illness that may interfere with study participation.
- Current substance use disorder.
- Current smoking or nicotine use, including cigarettes, cigars, electronic cigarettes, vaping products, or nicotine replacement therapy.
- History of anaphylaxis or severe allergic reaction to study-related dietary components.
- Planned major dietary change, initiation of a structured weight-loss program, or initiation of a specialized therapeutic diet during the study period.
- Concurrent participation in another interventional clinical trial.
- Any other medical, psychiatric, or social condition that, in the opinion of the investigator, could compromise participant safety, study compliance, or interpretation of study outcomes.
- Pregnancy or breastfeeding
- Known immunodeficiency state, including HIV infection, primary immunodeficiency, active hematologic or solid-organ malignancy under treatment, or other clinically significant immunocompromise, independent of medication use.
- Dysphagia or any condition impairing the ability to swallow oral capsules.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación factorial
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: FMT and Diet intervention
Participants will receive a once daily dose (4 pills) of young donor fecal microbiome transplant (FMT) for two weeks and a microbiome rejuvenating diet (MRD) intervention for 8 weeks.
The dietary intervention consists of dietitian-guided increase to ~3 servings/day fermented foods and ≥30-40 g/day or +20g fiber(plant-based whole food) and 5g of resistant starch and 5g of psyllium husk supplements over 8 weeks.
|
Each dose (4 capsules) will be taken daily in the morning on an empty stomach.
Clear liquids are allowed and regular breakfast can follow one hour later.
If the dose is skipped, the missed dose should be skipped and the standard 4-capsule dose resumed the following morning; doses must not be doubled.
There should be no solid food at the time of ingestion , solid food should be avoided at least 4 hours prior to ingestion of capsules, however, liquid diet is always allowed and a full glass of water should be taken after every dose ingestion.
The treatment will be administered daily for 2 weeks.
Otros nombres:
Fiber intake: participants will be instructed to increase their fiber intake to >30/40g or +20g per day . There will be a 1 week ramp-up period in which participants will increase their intake progressively. Detailed instructions will be provided to include a variety of fiber sources (legumes, seeds, whole grains, nuts, vegetables, and fruits). Participants will also be instructed to include 5g of resistant starch supplements and 5g of psyllium husk in their diet. Fermented food intake: participants will be instructed to add at least 3 portions of fermented food into their daily diet. There will be a 1 week ramp-up period in which participants will increase their intake progressively and maintain a high level of consumption for the following 8 weeks. Detailed instructions will be provided to include a variety of fermented foods (fermented dairy products, fermented vegetables, fermented non-alcoholic drinks, etc.). |
|
Experimental: FMT
Participants will receive a once daily dose of young donor FMT for two weeks.
|
Each dose (4 capsules) will be taken daily in the morning on an empty stomach.
Clear liquids are allowed and regular breakfast can follow one hour later.
If the dose is skipped, the missed dose should be skipped and the standard 4-capsule dose resumed the following morning; doses must not be doubled.
There should be no solid food at the time of ingestion , solid food should be avoided at least 4 hours prior to ingestion of capsules, however, liquid diet is always allowed and a full glass of water should be taken after every dose ingestion.
The treatment will be administered daily for 2 weeks.
Otros nombres:
|
|
Comparador activo: Placebo FMT and diet
Participants receive placebo pills that are identical in shape size and feel to the active therapeutic daily for 2 weeks and will comply with a microbiome rejuvenating diet (MRD) for 8 weeks.
The dietary intervention consists of dietitian-guided increase to ~3 servings/day fermented foods and ≥30-40 g/day or +20g fiber(plant-based whole food) and 5g of resistant starch and 5g of psyllium husk supplements over 8 weeks.
|
Fiber intake: participants will be instructed to increase their fiber intake to >30/40g or +20g per day . There will be a 1 week ramp-up period in which participants will increase their intake progressively. Detailed instructions will be provided to include a variety of fiber sources (legumes, seeds, whole grains, nuts, vegetables, and fruits). Participants will also be instructed to include 5g of resistant starch supplements and 5g of psyllium husk in their diet. Fermented food intake: participants will be instructed to add at least 3 portions of fermented food into their daily diet. There will be a 1 week ramp-up period in which participants will increase their intake progressively and maintain a high level of consumption for the following 8 weeks. Detailed instructions will be provided to include a variety of fermented foods (fermented dairy products, fermented vegetables, fermented non-alcoholic drinks, etc.).
Participants will receive a once daily dose (4 pills) of inactive pills that are identical in size, shape, color, taste and feel to the active FMT pills
|
|
Comparador de placebos: Placebo FMT
Participants receive placebo pills that are identical in shape size and feel to the active therapeutic daily for 2 weeks
|
Participants will receive a once daily dose (4 pills) of inactive pills that are identical in size, shape, color, taste and feel to the active FMT pills
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Difference in DunedinPACE
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in DunedinPACE among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by DNA methylation analysis of whole blood.
DunedinPACE is a DNA methylation biomarker that quantifies the pace of biological aging, reported as a rate of biological aging per chronological year; higher values indicate a faster pace of aging and lower values indicate a slower pace.
|
Baseline and 8 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Difference in Epigenetic Age
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in epigenetic age among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by epigenetic clocks (PC GrimAge, PC PhenoAge, and Horvath).
|
Baseline and 8 weeks
|
|
Difference in Telomere Length
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in telomere length among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by DNA methylation-based estimation.
|
Baseline and 8 weeks
|
|
Difference in Gut Microbial Alpha Diversity
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in gut microbial alpha diversity among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by the Shannon diversity index from shotgun metagenomic sequencing of stool.
|
Baseline and 8 weeks
|
|
Difference in Interleukin-6 (IL-6)
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in Interleukin-6 (IL-6) among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT).
|
Baseline and 8 weeks
|
|
Difference in High-Sensitivity C-Reactive Protein (hsCRP)
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in High-Sensitivity C-Reactive Protein (hsCRP) among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT).
|
Baseline and 8 weeks
|
|
Difference in Growth Differentiation Factor-15 (GDF-15)
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in Growth Differentiation Factor-15 (GDF-15) among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT).
|
Baseline and 8 weeks
|
|
Difference in Cytokines and Inflammatory Proteins
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in a panel of cytokines and inflammatory proteins, including CC- and CXC-motif chemokines (CCL and CXCL), among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by the NUcleic acid Linked Immuno-Sandwich Assay (NULISA™) and Olink proximity extension assay.
|
Baseline and 8 weeks
|
|
Difference in Gut Microbiome Composition
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in gut microbiome composition among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by shotgun metagenomic sequencing of stool.
|
Baseline and 8 weeks
|
|
Difference in Gut Microbial Beta Diversity
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in gut microbial beta diversity among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by between-sample dissimilarity from shotgun metagenomic sequencing of stool.
|
Baseline and 8 weeks
|
|
Difference in Gut Microbiome Functional Capacity
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in gut microbiome functional capacity among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by functional pathway and gene content profiling from shotgun metagenomic sequencing of stool.
|
Baseline and 8 weeks
|
|
Engraftment of Donor-Derived Microbial Strains
Periodo de tiempo: Baseline, 8 weeks, and 12 weeks
|
Detection, relative abundance, and persistence of donor-derived microbial strains in recipient stool in the FMT-treated groups compared with the placebo FMT groups, assessed by shotgun metagenomic sequencing.
|
Baseline, 8 weeks, and 12 weeks
|
|
Difference in Metabolomic Profiles
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in metabolomic profiles, including short-chain fatty acids, secondary bile acids, and aryllactates, among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by targeted and untargeted metabolomics of stool and blood.
|
Baseline and 8 weeks
|
|
Difference in Grip Strength
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in grip strength among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by hand dynamometry and measured in kilograms.
Higher values indicate greater muscle strength.
|
Baseline and 8 weeks
|
|
Difference in Timed Up and Go (TUG)
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in the Timed Up and Go (TUG) test among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), measured in seconds.
Lower values indicate better mobility.
|
Baseline and 8 weeks
|
|
Difference in Cognitive Function, Mini-Mental State Examination (MMSE)
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in cognitive function among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by the Mini-Mental State Examination (MMSE).
Scores range from 0 to 30; higher scores indicate better cognitive function.
|
Baseline and 8 weeks
|
|
Difference in Cognitive Function, Montreal Cognitive Assessment (MoCA)
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in cognitive function among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by the Montreal Cognitive Assessment (MoCA).
Scores range from 0 to 30; higher scores indicate better cognitive function.
|
Baseline and 8 weeks
|
|
Difference in Physical Function
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in self-reported physical function among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Function short form.
Scores are reported as T-scores standardized to a population mean of 50 and standard deviation of 10; higher scores indicate better physical function.
|
Baseline and 8 weeks
|
|
Difference in Fatigue
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in self-reported fatigue among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue short form.
Scores are reported as T-scores standardized to a population mean of 50 and standard deviation of 10; higher scores indicate greater fatigue.
|
Baseline and 8 weeks
|
|
Difference in Frailty
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in frailty among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by the FRAIL scale.
Scores range from 0 to 5; higher scores indicate greater frailty.
|
Baseline and 8 weeks
|
|
Difference in Weight
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in weight among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), measured in kilograms.
|
Baseline and 8 weeks
|
|
Difference in Body Mass Index (BMI)
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in Body Mass Index (BMI) among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), measured in kilograms per square meter.
|
Baseline and 8 weeks
|
|
Difference in Systolic Blood Pressure
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in systolic blood pressure among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), measured in millimeters of mercury.
|
Baseline and 8 weeks
|
|
Difference in Diastolic Blood Pressure
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in diastolic blood pressure among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), measured in millimeters of mercury.
|
Baseline and 8 weeks
|
|
Difference in Dietary Fiber Intake
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in total dietary fiber intake among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), measured in grams per day and assessed by 24-hour dietary recalls using the Nutrition Data System for Research (NDSR).
|
Baseline and 8 weeks
|
|
Difference in Fermented Food Intake
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in fermented food intake among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), measured in servings per day and assessed by 24-hour dietary recalls using the Nutrition Data System for Research (NDSR).
|
Baseline and 8 weeks
|
|
Incidence of Treatment-Emergent Adverse Events
Periodo de tiempo: Informed consent through 12 weeks
|
Number of participants with treatment-emergent adverse events and serious adverse events among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), with severity graded by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 and relatedness assessed by the investigator.
|
Informed consent through 12 weeks
|
|
Difference in Gastrointestinal and Systemic Tolerability Symptom Scores
Periodo de tiempo: Baseline and 8 weeks
|
Difference in the 8-week change from baseline in gastrointestinal and systemic tolerability symptom scores among the four randomized groups (FMT + MRD, FMT alone, MRD + placebo FMT, and placebo FMT), assessed by the weekly study tolerability questionnaire.
|
Baseline and 8 weeks
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Colaboradores
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
1 de diciembre de 2026
Finalización primaria (Estimado)
1 de enero de 2028
Finalización del estudio (Estimado)
1 de junio de 2028
Fechas de registro del estudio
Enviado por primera vez
25 de agosto de 2026
Primero enviado que cumplió con los criterios de control de calidad
14 de septiembre de 2026
Publicado por primera vez (Actual)
17 de septiembre de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
17 de septiembre de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
14 de septiembre de 2026
Última verificación
1 de septiembre de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRB-87419
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Sí
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .